Can breast cancer cause an elevated high‑sensitivity C‑reactive protein (hs‑CRP) level?

Can Breast Cancer Cause Elevated hs-CRP?

Yes, breast cancer can cause elevated hs-CRP levels, particularly in advanced disease stages, and elevated hs-CRP at diagnosis is associated with worse prognosis and reduced survival.

Evidence for the Association

The relationship between breast cancer and elevated hs-CRP is well-established in the research literature, though hs-CRP is not used diagnostically or for screening purposes in clinical guidelines.

Prevalence and Staging Correlation

Multiple studies demonstrate that hs-CRP levels correlate with breast cancer stage and burden:

• Elevated levels are common at diagnosis: In one cohort study, 86.7% of breast cancer patients had elevated CRP at the time of diagnosis 1
• Stage-dependent elevation: Higher CRP concentrations are more frequently observed in patients with advanced cancer compared to localized disease 2
• Significant elevation in malignant vs. benign disease: A case-control study found significantly elevated hs-CRP in patients with breast cancer compared to those with benign breast disease (P=0.000) 3

Prognostic Significance

Elevated hs-CRP at diagnosis predicts worse outcomes across multiple measures:

• Women in the highest tertile of CRP had a 1.94-fold increased risk of death (HR: 1.94,95% CI 1.48-2.55) and 1.76-fold increased risk of reduced disease-free survival compared to the lowest tertile 1
• The highest octile versus lowest octile showed a 2.51-fold increased mortality risk (HR: 2.51,95% CI 1.53-4.12) 1
• Patients with CRP ≥95th percentile (≥16.4 mg/L) had a 3.58-fold increased mortality risk (HR: 3.58,95% CI 2.36-5.42) 1
• Meta-analysis confirmed CRP's prognostic value with pooled HRs of 1.62 for overall survival, 2.08 for cancer-specific survival, and 1.81 for disease-free survival 4

Tumor Subtype Associations

The elevation appears particularly pronounced in certain breast cancer subtypes:

• HER2-positive tumors: Women with HER2-positive tumors in the highest CRP tertile had an 8.63-fold increased mortality risk (HR: 8.63,95% CI 2.04-36.4) 1
• Hormone receptor status: Elevated CRP was specifically associated with HR-positive/HER2-negative breast cancers 5

Population-Specific Considerations

The association is modified by patient characteristics:

• Postmenopausal and overweight women: The positive association between elevated CRP and breast cancer risk was predominantly observed in overweight postmenopausal women (OR: 2.78,95% CI 1.18-6.6 for highest vs. lowest quartile) 5
• BMI interaction: Combined high BMI (≥24 kg/m²) and high hs-CRP (≥3 mg/L) increased postmenopausal breast cancer risk 1.75-fold (HR: 1.75,95% CI 1.25-2.47) 6

Clinical Context and Limitations

Important Caveats

While breast cancer can elevate hs-CRP, several critical points must be considered:

1. Not diagnostically useful: Guidelines explicitly state that hs-CRP should not be used for screening or diagnosis of breast cancer due to low sensitivity 2

2. Multiple confounders: hs-CRP elevation can result from numerous non-cancer causes including obesity, metabolic syndrome, smoking, other inflammatory conditions, infections, and tissue damage 7, 8, 9

3. Overlap with benign conditions: The 10 mg/L cutoff traditionally used to exclude acute illness may inadvertently exclude patients with chronic inflammatory states relevant to cancer 9

4. Treatment effects: Chemotherapy itself can transiently increase CRP levels, with studies showing significant rises during adjuvant treatment 10, 11

Mechanistic Understanding

The elevation reflects tumor-driven systemic inflammation through:

• Spillover of tumor-derived cytokines (IL-1, IL-6, TNF-α) into systemic circulation 12
• Activation of the innate immune response with upregulated inflammatory pathways 12
• Hepatic acute-phase protein production in response to tumor-associated inflammation 13

Clinical Recommendation

When encountering elevated hs-CRP in a patient with known or suspected breast cancer:

• Do not use hs-CRP for diagnosis or screening - it lacks sufficient sensitivity and specificity
• Recognize it as a prognostic marker - elevated levels at diagnosis indicate more aggressive disease and worse outcomes
• Consider it in the context of staging - higher levels correlate with advanced disease and should prompt thorough metastatic workup if not already performed
• Account for confounders - evaluate for obesity, metabolic syndrome, infection, and other inflammatory conditions before attributing elevation solely to malignancy
• Monitor during treatment - recognize that chemotherapy can transiently elevate CRP, particularly in the first 4-6 weeks 14
• Use established tumor markers instead - CA 15-3 and CA 27.29 remain the reference markers for breast cancer monitoring 15, 2, 14